Journal Information
Vol. 71. Issue 1.
Pages 91-92 (01 January 2021)
Download PDF
More article options
Vol. 71. Issue 1.
Pages 91-92 (01 January 2021)
Letter to the Editor
DOI: 10.1016/j.bjane.2020.09.013
Open Access
Sedation during mechanical ventilation of COVID-19 patients in intensive care units into operating rooms
Igor Pedrosa Saffier
Corresponding author

Corresponding author.
, Rafael P. Kayano
Universidade de São Paulo (USP), Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil
Article information
Full Text
Download PDF
Full Text
Dear Editor,

Healthcare is a constitutional right in Brazil, where it is provided by public and private institutions. Its unified health system (SUS – Sistema Único de Saúde, in Portuguese) is universal and free for anyone. The Hospital das Clínicas (HC) is the tertiary teaching hospital of the Faculdade de Medicina da Universidade de São Paulo, Brazil, and is Latin America’s biggest hospital complex, with more than two thousand beds. Since March 2020, the Central Institute of HC provided 900 beds, being more than 300 of them dedicated to Intensive Care Units (ICUs), and it became a reference on how to handle the COVID-19 pandemic in Brazil, both for clinical assistance for infected patients and for research and innovation purposes.

In order to offer new venues for ICUs, 34 operating rooms were used to treat one to four patients according to the room size,1 providing 76 new ICU beds. As the amount of ICU ventilators was not sufficient to serve all the beds available in the hospital, anesthesia machines were used for this purpose. Considering that these devices work as a circuit, it raised concerns about the risk of CO2 rebreathing, which could lead to narcosis, impairing patient ventilation. However, no adverse events were reported. High flow ventilation was adopted to minimize this risk, preventing the need for frequent exchanges of soda lime.2 On the other hand, these devices allow the use of inhaled anesthetic drugs such as sevoflurane, that has already proved useful in ICU.3

In accordance with what has been reported by different health services around the world, in our practice, we have observed that COVID-19 patients require higher doses of sedatives than usual.4 The local protocol for patients under mechanical ventilation included the evaluation of the levels of sedation, by the Richmond Agitation and Sedation Scale (RASS), and pain, by the Behavioral Pain Scale (BPS). Deep sedation (RASS -4 or -5) was recommended for patients who needed this target to achieve protective mechanical ventilation, especially in the first 48 hours of critical illness. For patients without a proposal for extubation, sedation should be light to moderate (RASS -2 or -3), associated with daily awakening, and this assessment was performed every two hours.

Midazolam and fentanyl were recommended as initial sedoanalgesia, taking into account that these drugs were efficient at lower costs and required less replacements during the day, minimizing the exposure of the nursing staff to the virus. Continuous infusion of ketamine was as second-line therapy for agitation and pain-control optimization. The sedative recommended for the mild to moderate sedation phase was propofol in low doses. Dexmedetomidine could be used in patients with agitation close to extubation or as a second option in patients in the phase of light to moderate sedation for agitation control. For those patients with agitation or hyperactive delirium, neuroleptics such as quetiapine or risperidone were initiated via nasoenteral tube.

In case of impaired pulmonary compliance, severe ventilator asynchrony, or PaO2/FiO2 ratio lower than 150, even with the use of optimal doses of sedative agents and optimization of ventilator settings, the use of neuromuscular blockers was indicated. Cisatracurium was the neuromuscular blocker of choice when necessary, as it is the most studied drug in patients with acute respiratory distress syndrome. However, its use was not recommended for more than 48 hours due to the high risk of weakness and diaphragmatic dysfunction of the critical patient. Continuous administration was preferred over intermittent to minimize staff exposure, although this strategy may result in increased costs. The use of a neuromuscular transmission monitoring was indicated for patients under neuromuscular relaxation drugs. Additionally, for patients under neuromuscular blockade, we included the processed EEG monitoring to achieve adequate sedation levels. The depth of sedation was also monitored for those patients who are not under neuromuscular blockade but require higher doses of sedatives to minimize the agitation.

The adequate sedation for mechanical ventilation during the COVID-19 outbreak, based on scientific evidence and with a rational allocation of available healthcare resources can contribute for better outcomes of critical patients.

Conflicts of interest

The authors declare no conflicts of interest.

M.J.C. Carmona, V.C. Quintão, B.F. Melo, R.G. André, R.P. Kayano, L.M.S. Malbouisson, J.O.C. Auler-Júnior.
Transforming operating rooms into intensive care units and the versatility of the physician anesthesiologist during the COVID-19 crisis.
Clinics (Sao Paulo), 75 (2020), pp. e2023
M.L.A. Torres, F.A.T. Canhisares, V.C. Quintão.
Management of CO2 absorbent while using the anesthesia machine as a mechanical ventilator on patients with COVID-19.
Rev Bras Anestesiol, 70 (2020), pp. 184-185
M. Mesnil, X. Capdevila, S. Bringuier, P.-O. Trine, Y. Falquet, J. Charbit, et al.
Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam.
Intensive Care Med, 37 (2011), pp. 933-941
B.A. Orser, D.-S. Wang, W.-Y. Lu.
Sedating ventilated COVID-19 patients with inhalational anesthetic drugs.
EBioMedicine, 55 (2020),
Brazilian Journal of Anesthesiology (English Edition)

Subscribe to our newsletter

Article options